GlassScriptPhysician profile
Ann M Peck
NPI 1508903717
$3,391.30
in general payments reported to CMS, 2019-2025
23 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $208 · 2023: $1,139 · 2024: $702 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $554.32 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $442.37 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.25 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $265.75 | 2023-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $246.70 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $224.91 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $208.51 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $142.07 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $108.47 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $99.95 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $99.30 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Boston Scientific Corporation | $96.71 | 2023-2025 | Varithena Administration Pack |
| Alkermes, INC. | $85.12 | 2023 | Lybalvi, Aristada |
| Tris Pharma INC | $74.37 | 2023-2025 | Dyanavel Xr |
| Indivior INC. | $71.77 | 2022-2024 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.69 | 2022-2023 | |
| Lundbeck LLC | $60.65 | 2023-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $59.48 | 2022 | |
| Idorsia Pharmaceuticals US INC | $49.43 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $49.18 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $18.71 | 2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $17.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.